Onchilles Pharma closed a $25 million financing to advance a novel enzyme‑based cancer therapy modeled on a powerful immune enzyme into first‑in‑human studies. The startup’s approach engineers an immune‑derived enzyme to selectively kill tumor cells and aims for broad utility across solid tumors; the financing will support IND‑enabling studies and early clinical execution. Investors signaled confidence in an alternate modality to traditional biologics and cell therapies, and Onchilles positions the program as an asset that could complement existing immuno‑oncology strategies.